Literature DB >> 17151140

Reduced CD4+ subset and Th1 bias of the human iNKT cells in Type 1 diabetes mellitus.

Janos Kis1, Peter Engelmann, Klara Farkas, Geoffrey Richman, Shawn Eck, James Lolley, Heyam Jalahej, Maciej Borowiec, Sally C Kent, Andras Treszl, Tihamer Orban.   

Abstract

Invariant NKT (iNKT) cells are considered to be important in some autoimmune diseases including Type 1 diabetes mellitus (T1DM). So far, the published data are contradictory in regard to the role of iNKT cells in T1DM. We aimed to study iNKT cell frequency and the function of different iNKT cell subgroups in T1DM. We compared the results of four subject groups: healthy (H), long-term T2DM (ltT2DM; more than 1 year), newly diagnosed T1DM (ndT1DM; less than 3 months), and ltT1DM (more than 1 year) individuals. We measured the iNKT cell frequencies by costaining for the invariant TCR alpha-chain with 6B11-FITC and Valpha24-PE. After sorting the Valpha24+6B11+ cells, the generated iNKT clones were characterized. We tested CD4, CD8, and CD161 expression and IL-4 and IFN-gamma production on TCR stimulation. The CD4+ population among the iNKT cells was decreased significantly in ltT1DM versus ndT1DM, ltT2DM, or H individuals. The T1DM iNKT cell cytokine profile markedly shifted to the Th1 direction. There was no difference in the frequency of iNKT cells in PBMC among the different patient groups. The decrease in the CD4+ population among the iNKT cells and their Th1 shift indicates dysfunction of these potentially important regulatory cells in T1DM.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17151140     DOI: 10.1189/jlb.1106654

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  18 in total

1.  Genetic control of murine invariant natural killer T-cell development dynamically differs dependent on the examined tissue type.

Authors:  Y-G Chen; S-W Tsaih; D V Serreze
Journal:  Genes Immun       Date:  2011-09-22       Impact factor: 2.676

Review 2.  Prevention and treatment of type 1 diabetes mellitus by the manipulation of invariant natural killer T cells.

Authors:  Jan Novak; Lucie Novakova
Journal:  Clin Exp Med       Date:  2012-07-24       Impact factor: 3.984

3.  Characterization of human invariant natural killer T cells expressing FoxP3.

Authors:  Péter Engelmann; Klára Farkas; János Kis; Geoffrey Richman; Zhaoyun Zhang; Chong Wee Liew; Maciej Borowiec; Monika A Niewczas; Heyam Jalahej; Tihamér Orbán
Journal:  Int Immunol       Date:  2011-06-27       Impact factor: 4.823

4.  Activation of natural killer T cells promotes M2 Macrophage polarization in adipose tissue and improves systemic glucose tolerance via interleukin-4 (IL-4)/STAT6 protein signaling axis in obesity.

Authors:  Yewei Ji; Shengyi Sun; Aimin Xu; Prerna Bhargava; Liu Yang; Karen S L Lam; Bin Gao; Chih-Hao Lee; Sander Kersten; Ling Qi
Journal:  J Biol Chem       Date:  2012-03-06       Impact factor: 5.157

5.  High-parametric evaluation of human invariant natural killer T cells to delineate heterogeneity in allo- and autoimmunity.

Authors:  Tom Erkers; Bryan J Xie; Laura J Kenyon; Brian Smith; Mary Rieck; Kent P Jensen; Xuhuai Ji; Marina Basina; Samuel Strober; Robert S Negrin; Holden T Maecker; Everett H Meyer
Journal:  Blood       Date:  2020-03-12       Impact factor: 22.113

6.  Prevention of Type 1 Diabetes Mellitus using a Novel Vaccine.

Authors:  Tihamer Orban; Janos Tibor Kis
Journal:  Ther Adv Endocrinol Metab       Date:  2011-02       Impact factor: 3.565

Review 7.  Presumed guilty: natural killer T cell defects and human disease.

Authors:  Stuart P Berzins; Mark J Smyth; Alan G Baxter
Journal:  Nat Rev Immunol       Date:  2011-02       Impact factor: 53.106

8.  Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy.

Authors:  Tihamer Orban; Klara Farkas; Heyam Jalahej; Janos Kis; Andras Treszl; Ben Falk; Helena Reijonen; Joseph Wolfsdorf; Alyne Ricker; Jeffrey B Matthews; Nadio Tchao; Peter Sayre; Pete Bianchine
Journal:  J Autoimmun       Date:  2010-06       Impact factor: 7.094

Review 9.  Cell-based interventions to halt autoimmunity in type 1 diabetes mellitus.

Authors:  A E Barcala Tabarrozzi; C N Castro; R A Dewey; M C Sogayar; L Labriola; M J Perone
Journal:  Clin Exp Immunol       Date:  2013-02       Impact factor: 4.330

10.  Tissue-targeted therapy of autoimmune diabetes using dendritic cells transduced to express IL-4 in NOD mice.

Authors:  Rémi J Creusot; Shahriar S Yaghoubi; Keiichi Kodama; Demi N Dang; Vu H Dang; Karine Breckpot; Kris Thielemans; Sanjiv S Gambhir; C Garrison Fathman
Journal:  Clin Immunol       Date:  2008-03-12       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.